Greenway Greenhouse Cannabis Corporation (GWAYF) fair value: what the stock is really worth
As of Sep 28, 2026: fair value of Greenway Greenhouse Cannabis Corporation $0.18, price $0.06, upside +199.2%, quality 62 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Greenway Greenhouse Cannabis Corporation for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
45‑month range $0.0554 – $0.3562 · fair‑value band $0.1157 – $0.2689 · the $0.0612 price screens below the $0.1831 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Follow Greenway Greenhouse Cannabis in your weekly email
Every Wednesday you see whether Greenway Greenhouse Cannabis is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Greenway Greenhouse Cannabis Corporation engages in the cultivation, processing, sale, bulk package, and wholesale of dry bud cannabis. The company was incorporated in 2018 and is headquartered in Kingsville, Canada. Greenway Greenhouse Cannabis Corporation is a subsidiary of Sunrite Greenhouses Ltd.
Stock analysis
Greenway Greenhouse Cannabis Corporation (GWAYF) currently trades at $0.0612, while our model-based Fair Value estimate is $0.1831, implying the stock looks roughly 66.6% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $0.2500 per share, and 9 of the 10 models we run sit above the $0.0612 price.
Bear case: the Asset-Based group reads lowest at $0.0400, and 1 of the 10 models stay below the price. Evidence for this calculation is low.
Scenario range: $0.1157 (bear) to $0.2689 (bull), the price of $0.0612 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 62/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Greenway Greenhouse Cannabis Corporation reported revenue of C$8.9M in FY2025 versus C$1.2M in FY2021, a compound +66.8%/yr. Reported net income was −C$2.1M in FY2025.
Key figures
Market cap $8.8M · P/S ratio 1.47 · Net margin −23.0% · Return on equity −2.2% · Return on assets (EBIT) −5.7% · Operating margin 3.7% · Revenue (TTM) C$9.1M · Revenue growth (YoY) +40.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).
What moves the price
The share trades about 77% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 199%, GWAYF screens cheaper than that median.
Fair Value models
Bear $0.1157Fair Value $0.1831Bull $0.2689
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.67/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+71.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+65.2%
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−107.4% (2021) → −10.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−6.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (figures in CAD, Canada: IMF forecast 2.1% a year to 2030, 2.6% from 2016 to 2025) that is about −8.1% a year for the price.
Compare Greenway Greenhouse Cannabis Corporation with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 624 stocks
Beats the industry median on 7/11 measures
Overall it ranks above its industry peers.
Valuation
Quality Score62 · Above median
Fair Value upside+199.2% · Top 25%
Profitability
Return on assets1.7% · Below median
Net margin (TTM)−2.3% · Below median
Operating margin (TTM)3.7% · Below median
Growth and dividend
Revenue growth40.1% · Top 25%
Balance sheet
Debt / equity0.26× · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Greenway Greenhouse Cannabis Corporation (GWAYF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $0.1831 versus a price of $0.0612, about +199% upside (undervalued).
What is the fair value of GWAYF?
Our model-based fair value for Greenway Greenhouse Cannabis Corporation is $0.1831 (as of Sep 24, 2026), built from audited fundamentals. The current price: $0.0612.
What is the quality score of GWAYF?
Greenway Greenhouse Cannabis Corporation has a Quality Score of 62/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Greenway Greenhouse Cannabis Corporation (GWAYF)?
Our model-based price target is the fair value of $0.1831 (as of Sep 24, 2026) from 10 valuation models. Cautious scenario $0.1157, optimistic scenario $0.2689. It is a calculation from audited fundamentals, not an analyst target.
What is the Greenway Greenhouse Cannabis Corporation stock forecast for 2026?
Our models put fair value at $0.1831, about +199% upside versus a price of $0.0612 (undervalued). Cautious scenario $0.1157, optimistic scenario $0.2689. The calculation is refreshed regularly with new filings.
What is the revenue of Greenway Greenhouse Cannabis Corporation (GWAYF)?
Greenway Greenhouse Cannabis Corporation reported trailing-twelve-month revenue of about C$9.1M (latest available figure, as of Sep 24, 2026).
What growth is priced into Greenway Greenhouse Cannabis Corporation (GWAYF)?
For today's price to be fair in a discounted-cash-flow model, Greenway Greenhouse Cannabis Corporation would have to grow free cash flow by -6.1 % per year for five years (discount rate 8.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +66.8 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of GWAYF use?
Our models discount Greenway Greenhouse Cannabis Corporation at 8.5 %: a base by market capitalisation (nano), damped by beta 0.13, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Greenway Greenhouse Cannabis Corporation that is -6.1 % per year a year over ten years, using the same discount rate (8.5 %) and the same formula as our fair value.
How much growth has Greenway Greenhouse Cannabis Corporation (GWAYF) delivered so far?
Over the past 4 years revenue at Greenway Greenhouse Cannabis Corporation grew +66.8 % a year. The price currently implies -6.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Greenway Greenhouse Cannabis Corporation (GWAYF) growing?
The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into Greenway Greenhouse Cannabis Corporation (-6.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Greenway Greenhouse Cannabis Corporation (GWAYF)?
The free-cash-flow yield on the price is 14.06 %: that much free cash flow Greenway Greenhouse Cannabis Corporation produces per unit of market value. When it exceeds the discount rate of our models (8.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Greenway Greenhouse Cannabis Corporation (GWAYF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Greenway Greenhouse Cannabis Corporation it is $0.1831 per share (as of Sep 24, 2026), against a price of $0.0612. It is the blended result of 10 valuation models (cash flow, earnings, asset, dividend).
Is Greenway Greenhouse Cannabis Corporation stock overvalued or undervalued in 2026?
As of Sep 24, 2026, GWAYF trades below its calculated fair value: price $0.0612, fair value $0.1831, a gap of about +199% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GWAYF?
No. The price is what the market pays today ($0.0612); the fair value is what the company's own numbers justify ($0.1831). For Greenway Greenhouse Cannabis Corporation the two are $0.1219 per share apart. That gap is exactly why we show both numbers side by side.
How much is Greenway Greenhouse Cannabis Corporation worth?
The market values Greenway Greenhouse Cannabis Corporation at about $8.8M (market capitalisation, as of Sep 24, 2026). Per share that is $0.0612; our models calculate a fair value of $0.1831 per share.
What do the bullish and bearish scenarios say about GWAYF?
Our models span a range for Greenway Greenhouse Cannabis Corporation: cautious scenario $0.1157, base $0.1831, optimistic $0.2689 per share (as of Sep 24, 2026, price $0.0612). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Greenway Greenhouse Cannabis Corporation (GWAYF)?
Balance-sheet figures for Greenway Greenhouse Cannabis Corporation (as of Sep 24, 2026): return on equity −2.2%, debt of 0.26 per unit of equity. They feed the Quality Score of 62/100, which measures business quality independently of the share price.
How far is GWAYF from its 52-week high?
Greenway Greenhouse Cannabis Corporation trades at $0.0612, about 77% below its 52-week high of $0.2705 and 10% above the low of $0.0554 (as of Sep 28, 2026). Distance from the high says nothing about value: that is what the fair value of $0.1831 is for.
Which stocks are comparable to Greenway Greenhouse Cannabis Corporation?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Greenway Greenhouse Cannabis Corporation stock attractive at the current price?
The data as of Sep 24, 2026: price $0.0612, calculated fair value $0.1831 (+199%), Quality Score 62/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of GWAYF calculated?
We run Greenway Greenhouse Cannabis Corporation through 10 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.1831, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Greenway Greenhouse Cannabis Corporation currently trades 67 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Greenway Greenhouse Cannabis Corporation (GWAYF)?
The closing price on Sep 28, 2026 was $0.0612. Our model-based fair value is $0.1831, about +199% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Greenway Greenhouse Cannabis Corporation right now?
The price is below even our cautious bear case ($0.1157). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (62/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range ($0.1157 to $0.2689) leaves room in how you read the outcome.
Key figures of Greenway Greenhouse Cannabis Corporation
How large is the market capitalisation of Greenway Greenhouse Cannabis Corporation (GWAYF)?
The market capitalisation of Greenway Greenhouse Cannabis Corporation is $8.8M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Greenway Greenhouse Cannabis Corporation (GWAYF)?
The price-to-sales ratio of Greenway Greenhouse Cannabis Corporation is 1.47 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Greenway Greenhouse Cannabis Corporation (GWAYF)?
The net margin of Greenway Greenhouse Cannabis Corporation is −23.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Greenway Greenhouse Cannabis Corporation (GWAYF)?
The return on equity (ROE) of Greenway Greenhouse Cannabis Corporation is −2.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Greenway Greenhouse Cannabis Corporation (GWAYF)?
On an EBIT basis the return on assets of Greenway Greenhouse Cannabis Corporation is −5.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Greenway Greenhouse Cannabis Corporation (GWAYF)?
The operating margin of Greenway Greenhouse Cannabis Corporation is 3.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Greenway Greenhouse Cannabis Corporation (GWAYF)?
Revenue at Greenway Greenhouse Cannabis Corporation is growing +40.1% versus a year earlier (3y avg +65.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does Greenway Greenhouse Cannabis Corporation (GWAYF) carry?
The net debt of Greenway Greenhouse Cannabis Corporation is C$4.4M (fiscal year 2025, ≈ 2.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Greenway Greenhouse Cannabis Corporation in the live analysis
One click puts Greenway Greenhouse Cannabis Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 24, 2026